Applied Genetic Technologies Corporation Company Profile (NASDAQ:AGTC)

Applied Genetic Technologies Corporation trades on the NASDAQ under the ticker symbol "AGTC."

Applied Genetic Technologies Corporation (NASDAQ:AGTC) issued its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.04. The firm had revenue of $8.39 million for the quarter, compared to analyst estimates of $10.39 million. Applied Genetic Technologies Corporation had a return on equity of 6.62% and a net margin of 17.61%. Applied Genetic Technologies Corporation's revenue for the quarter was down 30.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.11 EPS. View Applied Genetic Technologies Corporation's Earnings History.

9 analysts have issued twelve-month target prices for Applied Genetic Technologies Corporation's stock. Their predictions range from $11.00 to $16.00. On average, they anticipate Applied Genetic Technologies Corporation's share price to reach $14.63 in the next twelve months. View Analyst Ratings for Applied Genetic Technologies Corporation.

Here are some recent quotes from research analysts about Applied Genetic Technologies Corporation stock:

• 1. According to Zacks Investment Research, "Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida. " (7/25/2017)
• 2. Rodman & Renshaw analysts commented, "A leader in AAV development; first-in-man data soon and critical to investment case. AGTC's AAV (adeno-associated virus) platform is based on a proprietary viral composition and manufacturing process that are backed by strong intellectual property positions. AGTC has the capability to target specific tissue types and drive gene expression appropriate for that tissue. We believe that there is great potential to treat an array of disorders that are monogenic (single gene) and autosomal recessive or X-linked. The company is currently targeting orphan ophthalmological indications with the goal of addressing the underlying biology of the disorder.Plenty of cash to fund development. We believe the preclinical data in hand support our projected outcome for positive results from the ongoing clinical programs. We are quickly approaching critical first-in-man data in mid-2017 from the company's lead program in XLRS and initial clinical data from the ACHM program by year-end 2017. We believe these data should help correct the valuation disconnect we call to investors' attention where the stock is trading below the company's cash balance, primarily due to the early stage nature of the platform. Additionally, the company has approximately two years of cash on hand to deliver to our development projections; furthermore, the trajectory should create inflection points that include the clinical data points mentioned as well as advancing more products into development." (3/15/2017)

Applied Genetic Technologies Corporation saw a decrease in short interest in June. As of June 30th, there was short interest totalling 253,618 shares, a decrease of 61.6% from the June 15th total of 659,977 shares. Based on an average trading volume of 427,007 shares, the short-interest ratio is currently 0.6 days. Approximately 2.2% of the shares of the stock are sold short.

Some companies that are related to Applied Genetic Technologies Corporation include Redhill Biopharma (RDHL), Summit Therapeutics PLC (SMMT), XBiotech (XBIT), AcelRx Pharmaceuticals (ACRX), Trevena (TRVN), Synthetic Biologics (SYN), Sorrento Therapeutics (SRNE), Conatus Pharmaceuticals (CNAT), Recro Pharma (REPH), Axsome Therapeutics (AXSM), Cellular Biomedicine Group (CBMG), Arrowhead Pharmaceuticals (ARWR), Verastem (VSTM), Cidara Therapeutics (CDTX), Agile Therapeutics (AGRX), Spring Bank Pharmaceuticals (SBPH), MannKind Corporation (MNKD) and OncoCyte Corp (OCX).

Applied Genetic Technologies Corporation's management team includes the folowing people:

• Scott Koenig M.D., Ph.D., Chairman of the Board
• Susan B. Washer, President, Chief Executive Officer, Director
• Lawrence E. Bullock, Chief Financial Officer
• Jeffrey D. Chulay M.D., Senior Vice President, Chief Medical Officer
• Mark Shearman Ph.D., Chief Scientific Officer
• Stephen B. Potter, Vice president and chief business officer
• Michael H. Goldstein, Chief Medical Officer
• David R. Guyer M.D., Director
• Ivana Magovcevic-Liebisch Ph.D. J.D., Director
• Anne M. VanLent, Director

Applied Genetic Technologies Corporation's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include InterWest Venture Management Co (8.05%), Acadian Asset Management LLC (3.92%), Municipal Employees Retirement System of Michigan (1.03%), Steinberg Global Asset Management (0.61%), Russell Investments Group Ltd. (0.43%) and Bank of Montreal Can (0.33%). Company insiders that own Applied Genetic Technologies Corporation stock include Ivana Magovcevic, Jeffrey D Chulay, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Institutional Ownership Trends for Applied Genetic Technologies Corporation.

Applied Genetic Technologies Corporation's stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Applied Genetic Technologies Corporation.

Applied Genetic Technologies Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Steinberg Global Asset Management, InterWest Venture Management Co and Bank of Montreal Can. Company insiders that have bought Applied Genetic Technologies Corporation stock in the last two years include Ivana Magovcevic, Lawrence E Bullock, Mark S Shearman and Stephen W Potter. View Insider Buying and Selling for Applied Genetic Technologies Corporation.

Shares of Applied Genetic Technologies Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Applied Genetic Technologies Corporation stock can currently be purchased for approximately $4.75.